A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate
Korean Journal of Hematology
;
: 73-75, 2010.
Artículo
en Inglés
| WPRIM
| ID: wpr-720282
ABSTRACT
Imatinib mesylate (IM) is used to treat a wide range of diseases, including Philadelphia chromosome-positive chronic myeloid leukemia (CML), on account of its high tolerability and low incidence of minor adverse events. Hemorrhage is thought to be a rare complication of IM. Recently, IM has been associated with reduced alpha2-plasmin inhibitor and platelet dysfunction. We report here the case of a 33-year-old female patient with CML who experienced subdural hematoma after an incremental increase in IM dosage due to a loss of complete molecular response. This case indicates that physicians should be alert to this atypical cause of headache in patients taking high-dose IM.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Piperazinas
/
Pirimidinas
/
Benzamidas
/
Plaquetas
/
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Philadelphia
/
Incidencia
/
Mesilatos
/
Mesilato de Imatinib
/
Cefalea
Tipo de estudio:
Estudio de incidencia
/
Estudio pronóstico
Límite:
Adulto
/
Femenino
/
Humanos
País/Región como asunto:
America del Norte
Idioma:
Inglés
Revista:
Korean Journal of Hematology
Año:
2010
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS